AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Tenaya Therapeutics Inc (NASDAQ:TNYA)
0.7309 USD
+0.005 0.675%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.726 |
|---|---|
| Change | +0.005 0.675% |
| 52 W H/L (in USD) | 8.091/1.660 |
| EBITDA (in USD) | -122.52M |
| PE Ratio | -- |
| Volume | 1843770 |
| Diluted Eps TTM | -1.65 |
| Total Assets (in USD) | 170.515M |
|---|---|
| Total Liabilities (in USD) | 31.091M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 45.681M |
| Market Cap (in USD) | 361.181 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
650 825 6990
Employees: 140
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Faraz Ali M.B.A. | CEO, Sec. & Director | 1973 |
| 2. | Dr. Deepak Srivastava M.D. | Scientific Founder, Chairman of Scientific Advisory Board & Director | 1967 |
| 3. | Ms. Leone D. Patterson M.B.A. | Chief Financial & Bus. Officer | 1963 |
| 4. | Dr. Whittemore G. Tingley M.D., PH.D. | Chief Medical Officer | 1968 |
| 5. | Dr. Eric N. Olson Ph.D. | Scientific Founder & Member of Scientific Advisory Board | NA |
| 6. | Dr. Bruce R. Conklin | Scientific Founder | NA |
| 7. | Dr. Saptarsi Haldar M.D. | Scientific Founder | NA |
| 8. | Dr. Sheng Ding | Scientific Founder | NA |
| 9. | Dr. Benoit G. Bruneau Ph.D. | Scientific Founder | NA |
| 10. | Dr. Kee-Hong Kim Ph.D. | Chief Technology Officer | 1966 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.010 0.021% | 47.1 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.160 2.477% | 48 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+6.780 1.447% | 471.38 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+5.400 0.874% | 621.63 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -123.665M | -72.721M | -38.395M | -26.231M |
| Minority Interest | - | - | - | - |
| Net Income | -123.663M | -69.652M | -38.308M | -25.778M |
| Selling General Administrative | 31.084M | 18.413M | 7.813M | 4.564M |
| Gross Profit | - | - | - | - |
| Reconciled Depreciation | 6.467M | 2.961M | 2.483M | 1.989M |
| Ebit | -132.088M | -75.767M | -38.912M | -27.712M |
| Ebitda | -125.621M | -72.806M | -36.429M | -25.723M |
| Depreciation And Amortization | 6.467M | 2.961M | 2.483M | 1.989M |
| Operating Income | -125.621M | -72.806M | -38.912M | -27.712M |
| Other Operating Expenses | 125.621M | 72.806M | 38.912M | 27.712M |
| Interest Expense | -0.002M | 72.733M | 0M | 0M |
| Tax Provision | 0M | 0M | 0M | 0M |
| Interest Income | 1.954M | 0.108M | 0.087M | 0.453M |
| Net Interest Income | 1.954M | 0.108M | 0.087M | 0.453M |
| Income Tax Expense | -0.002M | -3.069M | -0.087M | -0.453M |
| Total Revenue | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 125.621M | 72.806M | 38.912M | 27.712M |
| Cost Of Revenue | - | - | - | - |
| Total Other Income Expense Net | 1.956M | 0.085M | 0.517M | 1.481M |
| Net Income From Continuing Ops | -123.665M | -72.721M | -38.395M | -26.231M |
| Net Income Applicable To Common Shares | -123.665M | -72.721M | -38.395M | -26.231M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 170.515M | 278.945M | 314.189M | 148.161M | 38.001M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 6.94M | 7.227M | 4.058M | 1.429M | 1.117M |
| Total Liab | 31.091M | 278.945M | 35.663M | 229.476M | 81.74M |
| Total Stockholder Equity | 139.424M | 243.376M | 278.526M | -81.315M | -43.739M |
| Other Current Liab | 12.784M | 10.664M | 0.162M | 4.024M | 3.52M |
| Common Stock | 0.007M | 0.007M | 0.004M | 0.001M | 0.001M |
| Capital Stock | 0.007M | 0.007M | 0.004M | 0M | 0M |
| Retained Earnings | -403.282M | -279.198M | -155.533M | -82.812M | -44.417M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 4.793M | 4.126M | 1.012M | 0.684M |
| Cash | 45.681M | 95.272M | 38.129M | 128.535M | 23.872M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 22.733M | 24.248M | 21.774M | 5.041M | 4.12M |
| Current Deferred Revenue | - | - | 8.897M | - | - |
| Net Debt | -33.257M | -80.173M | -24.422M | -128.535M | -23.872M |
| Short Term Debt | 4.319M | 4.006M | 1.994M | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 12.424M | 15.099M | 13.707M | - | - |
| Other Stockholder Equity | 542.805M | 522.945M | 120.007M | 1.497M | 0.678M |
| Property Plant Equipment | - | 51.032M | 43.02M | 17.185M | 9.575M |
| Total Current Assets | 111.582M | 193.754M | 255.358M | 129.964M | 27.742M |
| Long Term Investments | 0M | 17.703M | - | - | - |
| Short Term Investments | 58.961M | 91.255M | 213.171M | 0M | 2.753M |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 5.63M | 9.578M | 10.721M | 1.017M | 0.6M |
| Accumulated Other Comprehensive Income | -0.106M | -0.378M | -0.141M | - | - |
| Non Currrent Assets Other | 4.995M | 4.793M | 4.126M | 1.012M | 0.684M |
| Non Current Assets Total | 58.933M | 85.191M | 58.831M | 18.197M | 10.259M |
| Capital Lease Obligations | 12.424M | 15.099M | 15.701M | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | 104.274M | -213.443M | 2.753M | -2.657M |
| Total Cashflows From Investing Activities | 83.652M | -238.564M | -7.01M | -5.583M |
| Total Cash From Financing Activities | 77.767M | 208.97M | 147.268M | 30.511M |
| Net Income | -123.665M | -72.721M | -38.395M | -26.231M |
| Change In Cash | 56.995M | -90.406M | 104.811M | 0.832M |
| Begin Period Cash Flow | 38.676M | 129.082M | 24.271M | 23.439M |
| End Period Cash Flow | 95.671M | 38.676M | 129.082M | 24.271M |
| Total Cash From Operating Activities | -104.424M | -60.812M | -35.447M | -24.096M |
| Depreciation | 6.467M | 2.961M | 2.483M | 1.989M |
| Other Cashflows From Investing Activities | 0.008M | 0.008M | 0.008M | 0.008M |
| Dividends Paid | - | - | - | - |
| Change To Inventory | - | - | - | - |
| Sale Purchase Of Stock | 77.767M | -0.013M | -0.001M | -0.003M |
| Other Cashflows From Financing Activities | 0.38M | 20.442M | 147.269M | 30.514M |
| Capital Expenditures | 20.63M | 25.121M | 9.763M | 2.926M |
| Change In Working Capital | -0.849M | 4.742M | -0.234M | -0.25M |
| Other Non Cash Items | 2.156M | 1.064M | -0.075M | 0.064M |
| Free Cash Flow | -125.054M | -85.933M | -45.21M | -27.022M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Select Biotechnology | 2 years ago | 2825413 |
| 2. | US Small-Cap Growth II Equity Comp | 2 years ago | 2577095 |
| 3. | T. Rowe Price New Horizons | 2 years ago | 2577095 |
| 4. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 1882246 |
| 5. | iShares Russell 2000 ETF | 2 years ago | 1085601 |
| 6. | BlackRock Health Sciences Opps Inv A | 2 years ago | 843991 |
| 7. | Fidelity Small Cap Growth | 2 years ago | 790790 |
| 8. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 689760 |
| 9. | BlackRock Health Sciences Term Trust | 2 years ago | 580851 |
| 10. | Fidelity Small Cap Index | 2 years ago | 473368 |
| 11. | iShares Russell 2000 Value ETF | 2 years ago | 427894 |
| 12. | T. Rowe Price New Horizons Tr-Z | 2 years ago | 390605 |
| 13. | Fidelity Small Cap Growth K6 | 2 years ago | 292920 |
| 14. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 289749 |
| 15. | Fidelity Extended Market Index | 2 years ago | 279891 |
| 16. | Tema Obesity & Cardiometabolic ETF | 2 years ago | 192591 |
| 17. | Bridgeway Ultra-Small Company Market | 2 years ago | 181900 |
| 18. | Vanguard Russell 2000 ETF | 2 years ago | 176261 |
| 19. | State St Russell Sm Cap® Indx SL Cl I | 2 years ago | 171289 |
| 20. | Galileo - Biotech Innovation Fund S USD | 2 years ago | 128982 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Column Group LLC | 2 years ago | 9400290 |
| 2. | Casdin Capital, LLC | 2 years ago | 6381377 |
| 3. | RA Capital Management, LLC | 2 years ago | 5507347 |
| 4. | BlackRock Inc | 2 years ago | 3786824 |
| 5. | T. Rowe Price Associates, Inc. | 2 years ago | 3346522 |
| 6. | Vanguard Group Inc | 2 years ago | 2862916 |
| 7. | Octagon Capital Advisors LP | 2 years ago | 2854000 |
| 8. | FMR Inc | 2 years ago | 2654751 |
| 9. | Euclidean Capital LLC | 2 years ago | 1015705 |
| 10. | Geode Capital Management, LLC | 2 years ago | 928763 |
| 11. | State Street Corporation | 2 years ago | 919222 |
| 12. | Alphabet Inc | 2 years ago | 915705 |
| 13. | Ghost Tree Capital, LLC | 2 years ago | 775000 |
| 14. | Renaissance Technologies Corp | 2 years ago | 482325 |
| 15. | StepStone Group LLC | 2 years ago | 462163 |
| 16. | Adage Capital Partners Gp LLC | 2 years ago | 400000 |
| 17. | Northern Trust Corp | 2 years ago | 389682 |
| 18. | Millennium Management LLC | 2 years ago | 375102 |
| 19. | Trustees Of Columbia University In The City Of New York | 2 years ago | 291828 |
| 20. | Morgan Stanley - Brokerage Accounts | 2 years ago | 232006 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...